e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic
Miriam J. Johnson, Janelle Yorke, John Hansen-Flaschen, Robert Lansing, Magnus Ekström, David C. Currow
Source:
Eur Respir J, 50 (3) 1701297; 10.1183/13993003.01297-2017
Journal Issue:
September
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Miriam J. Johnson, Janelle Yorke, John Hansen-Flaschen, Robert Lansing, Magnus Ekström, David C. Currow. Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. Eur Respir J, 50 (3) 1701297; 10.1183/13993003.01297-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Chronic cough: diagnosis, treatment and psychological consequences
Source: ISSN=ISSN 1810-6838, ISBN=, page=164
Year: 2006
Defining “stable chronic hypercapnia” in patients with COPD: the physiological perspective
Source: Eur Respir J, 55 (2) 1902365; 10.1183/13993003.02365-2019
Year: 2020
Defining “stable chronic hypercapnia” in patients with COPD: the physiological perspective
Source: Eur Respir J, 55 (2) 1902172; 10.1183/13993003.02172-2019
Year: 2020
Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice
Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies
Year: 2009
Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control
Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium
Year: 2008
Chronic respiratory symptoms but normal lung function: substantial disease burden but little evidence to inform practice
Source: Eur Respir J, 54 (3) 1901363; 10.1183/13993003.01363-2019
Year: 2019
Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice
Source: Eur Respir J 2013; 41: 1252-1256
Year: 2013
Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Bronchodiator therapy in COPD: physiological effects
Source: Breathe 2008; 4: 342-344
Year: 2008
Evaluation of adequacy of pharmacological treatment in relation to severity in patients with chronic obstructive pulmonary disease (COPD) and their clinical correlations.
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome?
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
A new perspective on concepts of asthma severity, control and optimum treatment
Source: Eur Respir J 2009; 33: 704-705
Year: 2009
Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis?
Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy
Year: 2017
Defining airflow limitation and chronic obstructive pulmonary disease: the role of outcome studies
Source: Eur Respir J 2015; 46: 8-10
Year: 2015
The relevance of respiratory muscle dysfunction and novel treatment options in COPD
Source: International Congress 2017 – PG18 Targeting the locomotor and respiratory muscles in chronic obstructive pulmonary disease: novel interventional tools and rehabilitation strategies
Year: 2017
The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD
Source: International Congress 2017 – COPD management
Year: 2017
The effect of regional differences on visual arts interpretation in exacerbation and stable periods of chronic airway diseases
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
The role of biomarkers in the management of severe asthma
Source: International Congress 2019 – Severe asthma guidelines: update 2019
Year: 2019
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept